Compare Neurocrine Biosciences Inc (NBIX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Teradyne, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Teradyne, Inc. trades at $383.25 (market cap $55.82B). The key difference: Teradyne, Inc. is far larger — about 3.5× Neurocrine Biosciences Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TER | |
|---|---|---|
Market Cap | $15.77B | $55.82B |
Sector | Health | Technology |
52-Week High | $185.50 | $483.84 |
52-Week Low | $123.10 | $112.24 |
Enterprise Value | $15.78B | $55.56B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Teradyne (TER) trades at $372.06, up 4.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $3.19B in 2025, and net income margin stands at 25.77%. Analyst sentiment is positive, with a consensus price target of $474.78 and no sell ratings among 31 analysts. Recent news highlights surging demand for UltraFLEXplus systems driven by AI and data center growth.
The outlook for TER is favorable, supported by robust AI-driven demand, earnings momentum, and institutional accumulation. Key risks include competitive pressures from KLA and Cohu, reliance on semiconductor cycles, and execution challenges in scaling operations. The stock offers upside potential but remains sensitive to tech sector volatility and macroeconomic conditions affecting capital expenditure trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
